Astex Pharmaceuticals, Inc. Message Board

from the In Briefing link regarding today's ASH presentation:

Excellent hypomethylation was achieved with higher doses in the daily regimen up to the Biologically Effective Dose (:BED). BED was reached before the Maximum Tolerated Dose (MTD). Of the 17 heavily pretreated relapsed/refractory AML patients who were given therapeutic doses of SGI-110 and achieved adequate hypomethylation, 5 major responses were observed.

Impressive. Lower toxicity. Ability to reach BED before hitting MTD. 5/17 major responses.
Impressive.